Accessibility Menu
Galmed Pharmaceuticals logo

Galmed Pharmaceuticals(NASDAQ) GLMD

Market Cap$4.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-74%
1 Month-8%
$0.53
+3.39%
+0.02Today
Galmed Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.532026-07-27
Galmed Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.41%USD 0.512026-07-20
1 month-8.11%USD 0.572026-06-26
3 month-10.54%USD 0.592026-04-28
Year to date-29.78%USD 0.752025-12-31
1 year-73.52%USD 1.992025-07-25
3 year-96.31%USD 14.282023-07-28
5 year-99.88%USD 444.602021-07-28
Since inception-99.98%USD 2,637.002014-03-14

Galmed Pharmaceuticals Financials at a Glance

Market Cap

$4.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.12M

EPS (TTM)

-$2.00

P/E Ratio

-0.26

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$0.53

Volume

60,583.741

Open

$0.50

Previous Close

$0.53

Daily Range

$0.50 - $0.55

52-Week Range

$0.41 - $2.03

Estimated Earnings Date

Jul 30, 2026

GLMD News

023 stock questions chalkboard

These Small Cap Biopharma Stocks Lost as Much as 34.1% in October. Are They Buys?

Maxx ChatskoNov 8, 2018
Liver

Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week

Brian Orelli, PhDJul 13, 2018
thumbs-up-three-surgeons-getty

3 NASH Stocks That Could Soar in the Second Half of 2018

Cory RenauerJun 15, 2018
liver

Are These Red-Hot NASH Stocks Still a Buy?

George Budwell, PhDJun 14, 2018
biotech2

Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today

George Budwell, PhDJun 12, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to developing innovative therapeutics for liver diseases. The company is primarily focused on Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule, currently in Phase III trials for treating non-alcoholic steato-hepatitis (NASH).

Products and Services
  • Aramchol for NASH treatment in overweight or obese patients
  • Amilo-5MER, a synthetic peptide for liver diseases
  • MyBiotics, currently in pre-clinical trials for NASH and fibrosis
Growth Outlook
  • Aramchol's Phase III study results could significantly impact market positioning
  • Collaboration with OnKai enhances AI-driven drug development capabilities
  • Potential expansion into the Republic of Korea through licensing agreements
Financial Highlights
  • Cash and short-term investments totaled $15.45 million as of March 31, 2026
  • Operating expenses for Q1 2026 were $2.04 million, reflecting ongoing R&D investments
  • Net income for Q1 2026 was -$1.91 million, indicating continued investment in growth
AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Allen J. Baharaff

Website

galmedpharma.com

Headquarters

Ramat Gan, TA 5250608, IL

GLMD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-64.10%

Return on Capital

-53.92%

Return on Assets

-69.35%

Earnings Yield

-3.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.26M

Volume

60.58K

Avg. Volume

727.92K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.29M

EBITDA

-$11.25M

Operating Cash Flow

-$7.68M

Capital Expenditure

$0.00

Free Cash Flow

-$7.68M

Cash & ST Invst.

$15.45M

Total Debt

$0.00

Galmed Pharmaceuticals Performance Analysis

Galmed Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Galmed Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Galmed Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -127.90-46.2%
20232023-12-31USD -29.95-76.6%
20242024-12-31USD -8.08-73.0%
20252025-12-31USD -2.39-70.4%
Galmed Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.6%
Q32025-09-3044.4%
Q42025-12-31-108.6%
Q12026-03-3160.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$706.35K

N/A

Employees

6

N/A

Net Income

-$1.91M

-73.0%

EBITDA

-$2.04M

-85.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$15.45M

-1.8%

Total Debt

$0.00

N/A

Accounts Receivable

$451.00K

+0.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-69.35%

N/A

Return on Invested Capital

-66.60%

N/A

Free Cash Flow

-$2.54M

-117.3%

Operating Cash Flow

-$2.54M

-117.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLECMoolec Science S.A.
$7.36+2.33%
INMInMed Pharmaceuticals Inc.
$1.64-4.09%
ELABPMGC Holdings Inc.
$0.92+2.21%
BDRXBiodexa Pharmaceuticals Plc
$1.57-4.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About GLMD

What is the current price of Galmed Pharmaceuticals?

Galmed Pharmaceuticals is trading at $0.53 per share.

What is the 52-week range for Galmed Pharmaceuticals?

Over the past 52 weeks, Galmed Pharmaceuticals has traded between $0.41 and $2.03.

How much debt does Galmed Pharmaceuticals have?

As of the most recent reporting period, Galmed Pharmaceuticals reported total debt of $0.00.

How much cash does Galmed Pharmaceuticals have on hand?

Galmed Pharmaceuticals reported $1.73M in cash and cash equivalents in its most recent financial results.

What is Galmed Pharmaceuticals’s dividend yield?

Galmed Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services